Catalyst
Slingshot members are tracking this event:
Phase 2 additional data of PB272 (Neratinib) (NSABP FB-7) in Neoadjuvant treatment for patients with HER2-positive breast cancer due 4Q 2016
- Source Link:
- http://www.pumabiotechnology.com/pr20160809.html
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PBYI | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 07, 2016
Occurred Source:
http://www.pumabiotechnology.com/pr20161207biomarker.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pb272, Neratinib, Nsabp Fb-7, Neoadjuvant Treatment, Her2-positive Breast Cancer
